Clinical trialNCT07108387RecruitingPhase 2Interventional

Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment78Giant Cell Arteritis (GCA)

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Sebastian H Unizony, M.D.
Massachusetts General Hospital: Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Emory University School of Medicine: Division of Rheumatology
Atlanta, Georgia, United States
Athanasios Tiliakos, DO
Recruiting
Northwestern University
Chicago, Illinois, United States
Anisha Dua, MD
Recruiting
Johns Hopkins Hospital: Division of Rheumatology Vasculitis Center
Baltimore, Maryland, United States
Brendan Antiochos
Recruiting
Massachusetts General Hospital: Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases
Boston, Massachusetts, United States
Sebastian Unizony, MD
Recruiting
Northwell Health: Division of Rheumatology and Allergy-Clinical Immunology
Great Neck, New York, United States
Lara El Khoury, MD
Recruiting
Hospital for Special Surgery, New York: Division of Rheumatology
New York, New York, United States
Not, yet, recruiting
University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology
Pittsburgh, Pennsylvania, United States
Robyn E. Domsic, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 11 Dec 2025
Primary completion: 11 Jun 2027
Completion: 11 Jan 2030
Last update posted: 5 Jun 2026
Registered enrollment: 78
Registry id: NCT07108387

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.